Edward Horn, PharmD, joined the Department of Pharmacy and Therapeutics at the School of Pharmacy in July 2018 and holds the title of Associate Professor. He also serves as a clinical pharmacist in heart transplantation and mechanical circulatory support with the University of Pittsburgh Medical Center Heart and Vascular Institute. In 2022, he was named as the Associate Director of the Cardiac Transplant Program at the UPMC Heart and Vascular Institute. He received his Doctor of Pharmacy degree from the University of Pittsburgh in 2000, with subsequent post-graduate training. Horn completed his PGY-1 Pharmacy Practice Residency at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. Upon completion, he returned to the University of Pittsburgh for his PGY-2 Specialty Residency in Critical Care Pharmacy Practice.
From 2002-2007, Horn was a clinical pharmacy specialist in Trauma/Surgical Critical Care at the Johns Hopkins Hospital in Baltimore, Maryland. During that time, he aided in the care of the critically ill and was active in both student and resident precepting, as well as clinical research. He then joined the pharmacy department at Allegheny General Hospital in Pittsburgh in 2007 as a clinical pharmacy specialist in cardiothoracic surgery with key roles in the in the cardiothoracic surgery ICU, heart transplant, and mechanical circulatory support programs there. He also served as the critical care pharmacy residency program director there from 2012 to 2018.
Horn's current clinical practice sites include the heart transplant clinic as well as the heart transplant/mechanical support service at UPMC. His clinical research interests surround improving the long-term care of both heart transplant recipients and patients with durable mechanical support devices, including immunosuppression management, management of antibody mediated rejections and highly sensitized patients, and anticoagulant/antiplatelet monitoring in mechanical circulatory support.
APPE Preceptor of the Year, University of Pittsburgh School of Pharmacy 2021-2022
Right Ventricular Mass Oversizing is Associated with Improved Post-transplant Survival in Heart Transplant Recipients with Elevated Transpulmonary Gradient
Hong Y, Hess NR, Ziegler LA, Dorken Gallastegi A, Iyanna N, Abdullah M, Horn ET, Mathier MA, Keebler ME, Hickey GW, Kaczorowski DJ.
Journal of Cardiac Failure 2024; October 28:
https://doi.org/10.1016/j.cardfail.2024.09.018
Clinical outcomes associated with diltiazem use in heart failure with reduced ejection fraction after implementation of a clinical support system.
Foster EM, Coons JC, Puccio EA, Sullinger DA, Ibrahim R, Ibrahim J, Hickey GW, Horn ET, Mosesso V, Rivosecchi RM
Annals of Pharmacotherapy 2024; April (online ahead of print)
https://doi.org/10.1177/10600280241243071
Cardiogenic shock etiology and exit strategy impact survival in patients with Impella 5.5.
Sicke M, Modi S, Hong Y, Bashline M, Klass W, Horn E, Hansra BS, Ramanan R, Fowler J, Sumzin N, Rivosecchi RM, Chaudhary R, Ziegler LA, Hess NR, Agrawal N, Kaczorowski DJ, Hickey GW
International Journal of Artificial Organs 2024; 47(1):8-16
https://doi.org/10.1177/03913988231214180
Reduction of HLA donor specific antibodies in heart transplant patients treated with proteasome inhibitors for antibody mediated rejection
Horn ET, Xu Q, Dibridge JN, Huston JH, Hickey GW, Kaczorowski DJ, Keebler ME, Zeevi A.
Clinical Transplantation 2023 December (37)12:e15132
https://doi.org/10.1111/ctr.15132
Basiliximab induction versus no induction in adult heart transplantation.
Rudzik KN, Rivosecchi RM, Palmer BA, Hickey GW, Huston JH, Keebler ME, Kaczorowski DJ, Horn ET.
Clinical Transplantation 2023; 37(5):e14937
https://doi.org/10.1111/ctr.14937
The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients.
Velleca A, Shullo MA, Dhital K, et al.
Journal of Heart and Lung Transplant Dec 2022; https://doi.org/10.1016/j.healun.2022.09.023
Served as expert reviewer for Task Force 1: Perioperative Care of the Heart Transplant Recipient and Task Force 2: Immunosuppression and Rejection
Outcomes of systemic bivalirudin and sodium bicarbonate purge solution for Impella 5.5.
Bashline M, Dibridge J, Klass WJ, Morelli B, Kaczorowski DJ, Schmidhofer M, Horn ET,
Gomez H, Ramanan R, Hickey GW, Rivosecchi RM.
Journal of Artificial Organs 2022 Oct 21. Artif Organs. 2022 Oct 21. doi: 10.1111/aor.14428. Online ahead of print.
PMID: 36271639
Apixaban as an alternative to warfarin for patients with a left ventricular assist device
Horn ET, Baker E, Dolphin J, Mitchell M, Modany A, Shullo MA, Coons JC.
Am J Health Sys Pharm 2022; 79(11): 826-829. doi: 10.1093/ajhp/zxac028.
Primary Graft Dysfunction in Heart Transplant Recipients – Risk Factors and Longitudinal Outcomes
Smith NF, Omran SS, Genuardi MV, Horn ET, Kilic A, Sciortino CM, Keebler ME, Kormos RL, Hickey GW.
American Society for Artificial Internal Organs Journal. 2022;68(3):394-401.
Outcomes of systemic anticoagulation with bivalirudin for Impella 5.0.
Fabrizio C, Levito M, Rivosecchi R, Bashline M, Slocum B, Killic A, Toma C, Murray H, Ramanan R, Fowler J, Hickey G, Horn ET.
International Journal of Artificial Organs 2021;44(10):681-686
Impact of Carfilzomib-based Desensitization in Heart Transplantation of Sensitized Candidates.
Sriwattanakomen R, Xu Q, Demehin M, Shullo MA, Mangiola M, Hickey GW, Sciortino CM, Horn ET, Keebler ME, Zeevi A.
Journal of Heart and Lung Transplantation 2021; 40(7): 595-603.
Nationwide Variability in the Use of Induction Immunosuppression for Adult Heart Transplantation. Diaz-Castrillon CE, Seese L, Mathier MA, Keebler ME, Hickey GW, McNamara D, Simon MA, Horn E, Kilic A. .
Journal of Cardiac Surgery 2020; 35(11): 3053-3061
Outcomes of Adult Heart Transplantation Using Hepatitis C Positive Donors
Kilic A, Hickey G, Mathier M, Sultan I, Gleason TG, Horn ET, Keebler ME.
Journal of the American Heart Association 2020 Jan 21;9(2):e014495
Sacha L, Moore CA, Iasella C, Keebler ME, Zeevi A, Xu Q, Kaczorowski DJ, Horn ET.
Presented at the American Transplant Congress 2024 Annual Meeting
June 1-5, 2024
Philadelphia PA
Daratumumab for refractory AMR rejection after adolescent heart transplant.
Skowronski J, Horn ET, Xu Q, Keebler ME
Presented at the International Society for Heart and Lung Transplant 44th Annual Meeting
April 10-13, 2024
Prague, Czechia
Advanced therapy eligibility in patients with axillary Impella for cardiogenic shock
Sicke M, Modi S, Schiemer M, Barrington W, Klass W, Ziegler K, Toma C, Horn E, Kaczorowski D, Ramanan R, Garvia V, Hickey GW.
Presented at CRF Technology and Heart Failure Therapeutics
March 4-6, 2024
Boston, MA
A brave new world: utilization of assisted reproductive technology after heart transplantation
Skowronski J, Hickey GW, Horn E, Rios J, Mathier MA, Levene J, Berlacher KL
Presented at the American College of Cardiology Annual Meeting (ACC.24)
Atlanta, GA
April 6-8, 2024
Bridging with BiVad: overcoming high allosensitization in peripartum cardiomyopathy
Skowronski J, Horn E, Keebler M, Ramana R, Hickey GW.
Presented at the American College of Cardiology Annual Meeting (ACC.24)
Atlanta, GA
April 6-8, 2024
Mechanical circulatory support prior to combined heart-kidney transplant – a long but worthy fight to fight
Jaramillo-Restreop V, Hess N, Horn E, Kaczorowski DJ, Hickey GW
Presented at the American College of Cardiology Annual Meeting (ACC.24)
Atlanta, GA
April 6-8, 2024
Treatment of Impella 5.5 purge dysfunction with tissue plasminogen activator prevents subsequent pump exchanges.
Sicke M, Klass W, Rivosecchi R, Bashline M, Fowler J, Horn E, Hess N, Kaczorowski D, Hickey W.
Presented at the American Society for Artificial Internal Organs Annual Meeting
San Francisco, CA
June 14-17, 2023
Significant reduction in donor specific antibodies in heart transplant patients treated with proteasome inhibitors for antibody mediated rejection.
Horn ET¸ Xu Q, Tushak Z, Dibridge JN, Huston JH, Hickey GW, Kaczorowski DJ, Keebler ME, Zeevi A.
Presented at the International Society for Heart and Lung Transplantation Annual Meeting
Boston, MA
April 26-29, 2022
A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart or lung transplantation
Rivosecchi RM, Silveira FP, Sacha LM, Horn ET, Keebler ME, Sanchez PG.
Presented at the International Society for Heart and Lung Transplantation Annual Meeting
Boston, MA
April 26-29, 2022
Basiliximab versus Methylprednisolone for induction in adult heart transplantation
Rudzik K, Rivosecchi RM, Edwards JN, Palmer BA, Hickey GW, Huston JH, Keebler ME, Kaczorowski DJ, Horn ET.
Presented at the International Society for Heart and Lung Transplantation Annual Meeting
Boston, MA
April 26-29, 2022
Treatment of antibody mediated rejection complicated but cardiogenic shock with a temporary left ventricular assist device as a bridge to recovery.
Fabrizio C, Horn ET, Stokes N, Rhinehart Z, Hickey GW, Keebler ME.
Presented at the International Society for Heart and Lung Transplantation Annual Meeting (Virtual)
April 24-28, 2021
Optimizing antibiotic therapy of ventricular assist device patients with driveline infections and associated bacteremias through the development of an antibiogram
Liang A, Hopwood-Brophy A, Horn ET.
Presented at The American Society of Health System Pharmacy Midyear Clinical Meeting
Virtual Meeting
December 6-10, 2020
